Donate

Blog

The Long Road to US Federal Insulin Law and What More Needs to be Done

The Long Road to US Federal Insulin Law and What More Needs to be Done

The journey to move towards a federal insulin price cap has been long and difficult, including challenging incremental steps. The fight for a true insulin price cap in the US continues. Read more

5 Ways To Combat Pharma Talking Points with Just the Facts

5 Ways To Combat Pharma Talking Points with Just the Facts

Misinformation about diabetes and insulin is all too regularly spread in both the media and on social platforms. In this post, we outline 5 of the most common talking points used to explain away price gouging and how we can use the facts to overcome this narrative. Read more

Calling for Empowered Implementation of Global Diabetes Coverage Targets

Calling for Empowered Implementation of Global Diabetes Coverage Targets

At the 75th World Health Assembly (WHA) of the World Health Organization (WHO), member states adopted the first ever ‘Global Diabetes Coverage Targets,’ meant to steer the course of diabetes diagnosis and treatment for the next 8 years. Read more

The Realities of Diabetes Burnout

The Realities of Diabetes Burnout

For too long, understanding the precise relationship between burnout and diabetes has been a mystery, and more data must be uncovered. Working with T1International, we are sharing a new survey on the impacts and implications of burnout for those with type 1 diabetes. Read more

T1International’s 2022 Out-of-Pocket Cost Survey: An Easy Way to Advocate

T1International’s 2022 Out-of-Pocket Cost Survey: An Easy Way to Advocate

Take the Survey! The survey is for individuals over the age of 18 with type 1 diabetes. A parent or caregiver can take the survey for those under the age of 18. Caregivers can also take the survey for spouses or partners. The survey is anonymous and is completely optional. Read more

Global Advocacy Success Series: Lejla Druškić, Bosnia and Herzegovina

Global Advocacy Success Series: Lejla Druškić, Bosnia and Herzegovina

Lejla Druškić, Global Advocate from Bosnia and Herzegovina, is a fearless speaker. Since joining T1International’s Global Advocacy Network in July 2021, she has been an invited speaker at the 3rd annual Congress of Diabetologists and Endocrinologists of Bosnia and Herzegovina, serving as a patient representative on a panel of patients and healthcare providers. Read more

Press Release: Human Rights Watch Calls Out Unaffordable Insulin as Human Rights Crisis

Press Release: Human Rights Watch Calls Out Unaffordable Insulin as Human Rights Crisis

A report from Human Rights Watch powerfully illustrates the human impact of sky-high insulin prices through the testimony of 18 insulin-dependent people living with diabetes in the United States.

Read more

T1International Statement on HR 6833 and the Affordable Insulin Now Act Vote

T1International Statement on HR 6833 and the Affordable Insulin Now Act Vote

On Thursday, March 31st, the US House of Representatives voted to pass a $35 insulin copay cap. The bill now heads to the Senate. While a $35 copay cap on insulin would impact many people, T1International is calling on the Senate to pass a true price cap on insulin for everyone, especially those without insurance. Read more

The Next 100 Years of Insulin

The Next 100 Years of Insulin

For some, the first 100 years of insulin has been a great, life-affirming success. For others, it has been a failure, where leaders and organizations in power have chosen profits over the lives and welfare of human beings. So how will we shape the next 100 years? Read more

6 Strategies for Ethical Patient Engagement

6 Strategies for Ethical Patient Engagement

More and more organisations today, from NGOs to global health alliances, are expressing a need for patient engagement and claiming to be patient-informed. As a patient-led organisation, we have noted that patient engagement is often well-intentioned but misguided. While patients might be acknowledged as experts on an event flyer or web page, that expert status does not necessarily mean they are compensated equitably or that their perspectives are valued and/or integrated comparably to other accepted experts, such as physicians or academic researchers. Read more